Reshma Rangwala
Executive VP, Chief Medical Officer & Head of ResearchDr. Reshma Rangwala, MD, Ph.D., serves as Executive Vice President and Chief Medical Officer at Karyopharm Therapeutics Inc since joining company in April 2022 and serves as its Head of Research since 2024. She is responsible for leading the Company's clinical development programs and strategy. She served as the Chief Medical Officer at Aravive, Inc. since September 2020 until March 28, 2022. Dr. Rangwala has more than a decade of experience in oncology and drug development. Previously, she served as Vice President, Medical, at Genmab where she led the clinical development program for a first-in-class antibody drug conjugate and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring and biologic licensing application preparations. Prior to that, she served as Executive Clinical Director at Merck & Co., where she was involved in the clinical development of KEYTRUDA in non-small cell lung cancer and gynecologic malignancies. She received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine. Dr. Rangwala completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, MO and her medical oncology fellowship at the Hospital of the University of Pennsylvania.
Positions
- Company NameKaryopharm Therapeutics Inc.Stock CodeKPTIQPositionExecutive VP, Chief Medical Officer & Head of ResearchColleagues
- RARichard A. PaulsonPresident, CEO & Director
- SPStuart PoultonExecutive VP & Chief Development Officer
- SSSharon ShachamCo-Founder & Chairman of Scientific Advisory Board
- LALori A. MacomberEVP, CFO & Treasurer
- BEBarry E. GreeneLead Independent Director
- DRDeepika Rachel PakianathanIndependent Director
- GGGaren G. BohlinIndependent Director
